157 terminated. 157 Phase 2, 14 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 157 | Terminated 157 |
| Phase 1 | 14 | Terminated 14 |
| Phase 3 | 9 | Terminated 9 |
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | BeiGene | 49 | 2025-08-21 | 2026-05-28 |
| A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip Zilretta, Triamcinolone Acetonide - Osteoarthritis of Hip | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 1 | 2025-07-25 | 2025-12-22 |
| A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis LY3541860 - Rheumatoid Arthritis | Phase 2 | Terminated | Eli Lilly and Company | 35 | 2025-03-19 | 2026-06-17 |
| Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis SclerFIX-IP - Osteoarthritis Hand | Phase 2 | Terminated | TBF Genie Tissulaire | 1 | 2024-10-07 | 2026-10-06 |
| Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1) Methotrexate - Arthritis, Arthralgia | Phase 2 | Terminated | AHS Cancer Control Alberta | 27 | 2024-08-12 | 2026-01-06 |
| A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome HZN-1116, Placebo - Sjogren's Syndrome | Phase 2 | Terminated | Amgen | 209 | 2024-05-09 | 2026-05-08 |
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis IHL-675A, Cannabidiol, Hydroxychloroquine - Rheumatoid Arthritis | Phase 2 | Terminated | Incannex Healthcare Ltd | 20 | 2023-11-22 | 2026-03-27 |
| A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain GSK3858279, Placebo - Pain, Osteoarthritis, Knee | Phase 2 | Terminated | GlaxoSmithKline | 314 | 2023-09-13 | 2025-11-10 |
| A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis TQH3821 tablets 200 mg, TQH3821 tablets matching placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 195 | 2023-08-30 | 2025-02-20 |
| CD40L Antagonism in Rheumatoid Arthritis (RA) Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi - Rheumatoid Arthritis | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2023-07-25 | 2026-07-20 |
| Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA Active tcVNS, Sham tcVNS - Juvenile Idiopathic Arthritis (JIA) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2023-06-27 | 2025-11-25 |
| Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline - Knee Osteoarthritis | Phase 2 | Terminated | MiMedx Group, Inc. | 43 | 2023-03-24 | 2024-01-17 |
| VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) Dose A VTX958, Dose B VTX958, Placebo - Psoriatic Arthritis | Phase 2 | Terminated | Ventyx Biosciences, Inc | 205 | 2023-01-31 | 2024-12-27 |
| Biological Response to Platelet-rich Plasma and Corticosteroid Injections Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj - Knee Osteoarthritis | Phase 1 / Phase 2 | Terminated | University of Missouri-Columbia | 23 | 2022-12-28 | 2025-06-25 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA QUC398, Placebo - Osteoarthritis, Knee | Phase 2 | Terminated | Novartis Pharmaceuticals | 101 | 2022-11-09 | 2026-03-31 |
| Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease ALLN-346, Placebo - Hyperuricemia, Gout | Phase 2 | Terminated | Allena Pharmaceuticals | 19 | 2022-09-02 | 2023-06-23 |
| Astaxanthin for Management of Inflammation in Knee Osteoarthritis Astaxanthin, Placebo - Osteoarthritis, Knee, Osteoarthritis Knees Both | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 16 | 2022-09-02 | 2025-05-20 |
| A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis Peresolimab, Placebo - Rheumatoid Arthritis, Arthritis | Phase 2 | Terminated | Eli Lilly and Company | 491 | 2022-08-31 | 2025-12-04 |
Showing 20 of 157. Sign in to see all of them.
Arthritis, Rheumatoid (81) · Osteoarthritis (27) · Osteoarthritis, Knee (24) · Pain (12) · Arthritis, Psoriatic (11) · Sjogren's Syndrome (8) · Autoimmune Diseases (7) · Osteoarthritis, Hip (7) · Spondylitis, Ankylosing (7) · Arthralgia (5) · Arthritis, Juvenile (5) · Inflammation (5) · Musculoskeletal Diseases (5) · Gout (4)
Joint Diseases (154) · Musculoskeletal Diseases (152) · Rheumatic Diseases (133) · Skin and Connective Tissue Diseases (102) · Immune System Diseases (90) · Connective Tissue Diseases (89) · Autoimmune Diseases (85) · Pathological Conditions, Signs and Symptoms (26) · Bone Diseases (22) · Spinal Diseases (20) · Spondylarthritis (20) · Spondylitis (20) · Spondylarthropathies (19) · Signs and Symptoms (17)
Methotrexate (18) · Naproxen (5) · fostamatinib (5) · Adalimumab (4) · Celecoxib (4) · Methylprednisolone (4) · Rituximab (4) · Abatacept (3) · Infliximab (3) · Saline Solution (3) · Sodium Chloride (3) · Triamcinolone (3) · ocrelizumab (3) · sarilumab (3) · Diclofenac (2)
Pfizer (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Biogen (6) · AstraZeneca (5) · Eli Lilly and Company (5) · Novartis Pharmaceuticals (5) · Amgen (4) · Hoffmann-La Roche (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · Merck Sharp & Dohme LLC (4) · AbbVie (3) · Bristol-Myers Squibb (3) · GlaxoSmithKline (3) · Pacira Pharmaceuticals, Inc (3) · Advanced Accelerator Applications (2)
United States (102) · Poland (45) · Spain (33) · Germany (29) · United Kingdom (29) · Czechia (28) · Hungary (28) · Canada (27) · Mexico (21) · Belgium (16) · Argentina (15) · Australia (15) · Italy (14) · Netherlands (14) · Russia (13)
Betty Diamond, MD (2) · Christopher Striebich, MD, PhD (2) · Cynthia Aranow, MD (2)
PMID 33254235, PMID 15039276, PMID 18565256, PMID 18587624, PMID 20052461, PMID 21128258, PMID 21360491, PMID 22247354, PMID 22251436, PMID 22337568, PMID 23559821, PMID 25035839, PMID 25074688, PMID 25779750, PMID 26773108, PMID 27238963, PMID 27748055, PMID 28207896, PMID 28287489, PMID 29343509, PMID 29361199, PMID 30032191, PMID 30240937, PMID 31628482, PMID 31901394, PMID 32551947, PMID 33323529, PMID 34505846, PMID 34945097, PMID 35137002, PMID 36456835, PMID 37162744, PMID 37831074, PMID 37932009, PMID 40676732, PMID 40747756, PMID 40787733, PMID 40884017, PMID 41289027, PMID 41388232, PMID 42167889
2009 (4), 2016 (4), 2018 (4), 2014 (2), 2015 (2), 2017 (2), 2023 (2), 2004 (1), 2008 (1), 2019 (1), KL2TR003168 (1), P01NS119159 (1), P20GM130414 (1)